



Medint - Medical intelligence

Technology Review

How to effectively deal with the need for repeated blood tests for chronic patients?

April 2021



Many oncologic patients who are treated with chemotherapy, or other patients who need to monitor their white blood cells, are telling about the pain and difficulties of the routine blood workups. This everyday operation causes great suffering for these patients. Therefore they are looking for a non-invasive and not painful method to check their blood count.

Here we present some of the newest technologists who try to solve this problem.

1. [Leuko - PointCheck](#)

What is it? A noninvasive device for the screening of severe neutropenia by imaging the blood flowing through the capillaries in the finger.

Stage of development: There is a [clinical trial](#) testing this technology for detecting chemotherapy-induced neutropenia at Boston Medical Center. Contacts: Álvaro

Sánchez-Ferro, MD Phone: +34619223086

Mail: alvaro@leuko.io



How to get it?

- Company contact email: contact@leuko.com
- Addresses:
 - 8 St. Marys Street, Boston, MA 02215, USA
 - Calle de Irún 23, Madrid, 28008, Spain



2. VainViewer

What is it? A vein visualization product designed to provide an accurate image of patient veins.

Stage of development

- VeinViewer is a registered trademark of Christie Medical Holdings, Inc.
- A [study](#) tested if the product would increase the success rates of peripherally inserted central catheters (PICCs) in neonates insertion. It was shown that Vein Viewer was significantly more likely to lead to successful line placement.



How to get it?

- Mail: medinfo.us@bbraunusa.com
- Phone: 1-800-854-6851
- Address: 824 12th Avenue Bethlehem, 18018 Pennsylvania USA

3. Sight OLO – a CBC Analyzer (Sight Diagnostics, Israel)

What is it?

- Sight OLO is a non-invasive device (taken from a finger prick) that provides 5-part CBC results with 19 parameters and sophisticated flagging capabilities at the point of care.
- It is the first CBC analyzer that is FDA 510(k) cleared for blood taken directly from either a finger prick or a venous sample.



Stage of development: Sight OLO has been validated for patients aged 3 months and above in a variety of clinical settings such as oncology, pediatrics, and urgent care settings. The possibility of processing finger prick samples in a field hospital or remote clinics makes Sight OLO accessible to the most delicate patients and situations.